T he morbidity and mortality associated with peripheral artery disease (PAD) is an expanding unmet medical need as a consequence of the ageing population and growing prevalence of metabolic disorders.
1,2 PAD affects >200 million individuals worldwide and typically manifests as intermittent claudication, but often progresses to, or even presents as, critical limb ischemia (CLI) characterized by pain, ulceration, and gangrene; many patients face amputation and early death. 1, 2 The pathology is triggered by atherosclerotic vascular occlusions and is underpinned by an insufficient angiogenic (hypoxia-triggered de novo blood vessel formation) and arteriogenic (shear stress-induced remodeling of the collateral network) response, compensatory and complementary mechanisms invoked to reinstate blood supply to the ischemic tissue. 3 A central pathway coordinating both processes is driven by vascular endothelial growth factor (VEGF)-A, 4 which preclinical studies indicated was a potential treatment for PAD. 5 However, large-scale clinical trials using VEGF-A to promote angiogenesis and arteriogenesis in patients with PAD and CLI have proven disappointing. [6] [7] [8] Therefore, delineation of the mechanisms and signaling pathways that underlie these intrinsic, restorative pathways is critical if the therapeutic potential of a proangiogenic strategy is to be harnessed.
The endothelium is pivotal in triggering angiogenesis, vascular remodeling, and minimizing functional deficit after ischemia. 9 Endothelium-derived C-type natriuretic peptide (CNP) plays a fundamental role in regulating vascular homeostasis [10] [11] [12] ; CNP controls local blood flow in the resistance vasculature and systemic blood pressure, reduces the reactivity of leukocytes and platelets, and prevents the development of atherogenesis and aneurysm. Several facets of CNP biology suggest it may play a central role in angiogenesis. For instance, 2 of the primary stimuli for CNP release from endothelial cells are shear stress 13 and transforming growth factor β, 14 both of which are well-validated triggers for angiogenesis and arteriogenesis. In addition, hypoxia-inducible factor 1α, a fundamental driver of the ischemic angiogenic response, is a potent enhancer of natriuretic peptide expression, in particular, in cardiomyocytes. 15 Our previous studies revealed that pulmonary microvascular endothelial cells from endothelium-specific CNP -/-(ecCNP -/-) and global NPR-C -/-mice proliferate significantly more slowly than wildtype (WT) cells, 16 implying that CNP has a physiological role in regulating growth. The peptide also slows neointimal hyperplasia and promotes reendothelialization in vein grafts, 17 in damaged carotid arteries, 18 and after balloon angioplasty. 19, 20 CNP also maintains capillary density after myocardial infarction 21 and hindlimb ischemia. 22 Although these observations intimate that pharmacological administration of CNP may promote arteriogenesis and angiogenesis, previous work has reported that CNP blocks VEGF signaling to attenuate angiogenesis in vitro, 23 and reduces sponge implant neovascularization in vivo, 24 demonstrating that the function of CNP in this setting remains unclear and requires further investigation. Moreover, there is no evidence demonstrating that endothelium-derived CNP either directly stimulates angiogenesis or triggers endothelial cell processes critical for angiogenesis. Therefore, given recent findings showing an important role for CNP in vascular homeostasis, [10] [11] [12] we sought to investigate whether endogenous CNP is a key regulator of angiogenesis and vascular remodeling.
METHODS

Ethical Permission
All murine studies conformed to the UK Animals 
Clinical Perspective
What Is New?
• Angiogenesis and arteriogenesis are harmonized responses to ischemia (eg, peripheral artery disease and myocardial infarction) that restore tissue perfusion.
• This study defines a central (patho)physiological role for endothelium-derived C-type natriuretic peptide, via activation of cognate natriuretic peptide receptor-C, in angiogenesis and vascular remodeling.
• Moreover, the work demonstrates the therapeutic utility of pharmacologically targeting natriuretic peptide receptor-C to restore deficits in these processes after ischemia and injury.
What Are the Clinical Implications?
• Previous approaches aimed at facilitating angiogenesis in peripheral artery disease have proven ineffective in clinical trials; the only currently effective management is surgery.
• The novel signaling system we have identified offers promise to radically improve and resolve the poor perfusion in patients with peripheral artery disease, reducing the need for invasive intervention and amputation.
• Targeting the C-type natriuretic peptide/natriuretic peptide receptor-C pathway may therefore offer a tangible pharmacological approach to improve peripheral artery disease and other ischemic cardiovascular disorders.
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declare that all supporting data are available within the article (and its online-only Data Supplement).
Endothelial 3-Dimensional Tube Formation Assay
Primary murine pulmonary endothelial cells (PMECs) were isolated as we have described previously. 16 PMECs were resuspended in diluted endothelial cell growth medium (1:3 in Dulbecco modified Eagle medium/nutrient mixture F-12) and plated on 15 mg/mL reduced-growth factor extracellular matrix (Cultrex, Trevigen) at a density of 1.75×10 5 cells/cm 2 . Tubule formation was determined by measuring branch number and length by using National Institutes of Health ImageJ software, 2, 4, and 6 hours after treatment with CNP (1 nmol/L to 1 µmol/L, GenScript) or VEGF (30 ng/mL, Pre-protech).
Tubule formation in human umbilical vein endothelial cells (HUVEC) was measured after treatment with CNP (1 nmol/L) or atrial natriuretic peptide (ANP) (10 nmol/L) in the absence or presence of selective NPR-C antagonist M372049 (10 µmol/L), the selective phosphoinositide 3-kinase γ (PI3Kγ) inhibitor AS605240 (100 nmol/L; Sigma), or the selective protein kinase G (PKG) blocker KT5283 (2 μmol/L; Sigma) over a 16-hour period. A cohort of cells was transfected using lipofectamine 2000 (Thermofisher Scientific) with either nonspecific small interfering RNA (Mission Control, Sigma Aldrich), NPR-B-or NPR-C-specific small interfering RNA (Sigma Aldrich) and were treated with CNP or the selective NPR-C agonist, cANF [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] (2 nmol/L). Silencing of NPR-B and NPR-C was confirmed at the mRNA and protein level by using reverse transcription polymerase chain reaction and immunoblot ( Figure IA through IC in the online-only Data Supplement).
Cell Migration Assay
Endothelial cells were plated in gelatin-coated wells of a 96-well plate (Corning Biocoat) at a density of 1.75×10 5 cells/ cm 2 and left to reach confluence. A scratch was performed using a 10-μL sterile pipette, and images were taken at regular intervals over a 24-hour period to monitor scratch closure. Cell populations were treated with CNP (1 nmol/L to 1 µmol/L) or VEGF (30 ng/mL).
Aortic Sprouting Assay
Mice were killed by cervical dislocation, and thoracic aortas were removed, trimmed of all extraneous tissue, and flushed with media via the lumen to remove all blood. Rings of ≈0.5 mm were cut and embedded in 1 mg/mL collagen matrix (type 1 rat tail, Millipore) and incubated for 1 hour at 37°C. Opti-MEM + Glutamax media (Opti-MEM, Gibco) containing 2.5% bovine serum (Gibco), 50 U/mL penicillin, and 0.5 mg/ mL streptomycin (Sigma-Aldrich) and either CNP (1 nmol/L to 1 µmol/L) or VEGF (30 ng/mL) or was added to the wells. Interventions were refreshed every 2 days and images of sprouting aortas were obtained after 7 days.
Matrigel Plug Neovascularization
Mice were injected subcutaneously with 15 mg/mL reducedgrowth factor extracellular matrix (Cultrex, Trevigen) containing 30 ng/mL VEGF (Pre-protech) and 50 U heparin (Pfizer), which formed a solid plug at body temperature. Plugs were extracted after 14 days and homogenized in 0.5 mL of cell lysis buffer and centrifuged at 6000g at 4°C for 60 minutes. Hemoglobin was detected at 400 nm wavelength by using a colorimetric assay (Sigma-Aldrich). Histological analysis of fixed and paraffin-embedded matrigel plugs was performed using hematoxylin and eosin and isolectin B4 staining.
Hindlimb Ischemia
Mice were anesthetized with 1.5% to 2% isoflurane vaporized in oxygen, placed on a heated blanket to maintain body temperature, and a small incision (≈10 mm) was made in the hindlimb skin directly over the femoral vasculature. All mice received preoperative analgesia (buprenorphine, 0.1 mg/kg, Vetergesic, Alstoe Animal health). A portion of the femoral artery was exposed via a 2-cm incision, and 2 ligations were performed using 8 nylon sutures, first distal to the origin of the profunda femoris artery and second proximal to the saphenous artery. The femoral artery was then excised between the ligation sites and the skin was closed with noncontinuous absorbable suture. Noninvasive laser Doppler imaging (Moor LDI2, Moor Instruments Ltd) was used to assess hindlimb blood flow at baseline and immediately after undergoing hindlimb ischemia (HLI), with subsequent imaging at day 3, 7, 14, 21, and 28 post-HLI. The rate of reperfusion in the hindlimb was calculated as a ratio of blood flow in the ipsilateral ischemic versus contralateral nonischemic limb. In some experiments, mice were implanted with osmotic minipumps (1002; Alzet) containing CNP (0.2 mg·kg -1 ·d -1 ) at day 0 to explore if any phenotype produced by gene knockout could be reversed by pharmacological application of the peptide. At the end of the study (day 28), mice were briefly anesthetized with isoflurane and blood was collected via cardiac puncture. Mice were culled by cervical dislocation, and the gastrocnemius muscle from each leg was harvested for postanalysis. In some experiments, the gastrocnemius muscle from each leg was harvested at day 3 and day 7 post-HLI from WT mice, treated with an RNA stabilizer (RNAlater, Sigma), and stored at -20°C before RNA isolation.
Carotid Injury
Mice were anesthetized using 1.5% to 2% isoflurane in oxygen. Left internal carotid arteries were exposed and isolated from surrounding nerves and tissue. A 0.35-mm wire catheter was introduced via a small incision and inserted and extracted repeatedly, 3 times, over ≈15-mm length of vessel, to remove the endothelial cell layer. Vessels were then tied and skin sutured using sterile 6-0 silk and mice allowed to recover. Mice were given buprenorphine (0.1 mg/kg) at the beginning of surgery for the management of postsurgical pain. After 14 days, mice were anesthetized with sodium pentobarbital (100 mg/mL). Blood was cleared using phosphate-buffered saline, and mice were then perfusion fixed with 4% paraformaldehyde at 100 mm Hg. Injured left and control right carotid arteries were dissected out and embedded in paraffin. Four-micrometer sections every 500 μm were cut and stained with hematoxylin and eosin and α-smooth muscle actin (1:5000) for histological analysis. Vessel dimensions were measured using ImageJ analysis after calibration with a ORIGINAL RESEARCH ARTICLE micrometer on hematoxylin and eosin-stained sections, and the intima:media thickness ratio was calculated.
Cutaneous Wound Healing
The rate of skin wound closure after injury was determined using a cutaneous wound healing model. Mice were anesthetized with 1.5% to 2% isoflurane in oxygen and the dorsal skin was shaved and cleaned with alcohol. Per mouse, one bilateral full-thickness skin wound was created, using a sterile 3-mm biopsy punch on the dorsal rostral back skin without injuring the underlying muscle. Wounds were digitally photographed at 0, 4, and 7 days after injury by using a digital camera (Sony Europe Limited).
Protein and mRNA Quantification and Immunohistochemistry
These were conducted according to standard protocols. Further information can be found in the online-only Data Supplement Information and Table I in the online-only Data Supplement.
Data Analysis
Results are expressed as mean±SEM, and the n value denotes the number of animals or independent experiments per group. Statistical analyses were performed (GraphPad Prism version 6; GraphPad) using the Student t test, 1-way or 2-way ANOVA with Bonferroni post hoc tests as appropriate.
RESULTS
Expression of CNP and NPR-C Are Downregulated in Human Patients With CLI
Expression of VEGF-A and VEGF receptor 2 mRNA was significantly reduced, whereas hypoxia-inducible factor 1α, Bax (apoptosis regulator Bcl-2 associated X protein), VCAM-1 (vascular cell adhesion protein-1), interleukin-6, and C-C Motif Chemokine Ligand 2 mRNA were all elevated in gastrocnemius muscle biopsies from patients with CLI in comparison with healthy controls, commensurate with a compromised angiogenic, remodeling environment 25, 26 ( Figure IIA in the onlineonly Data Supplement). Evidence that CNP/NPR-C signaling might be critical to a proangiogenic, proarteriogenic host defense response to ischemia was provided by a parallel reduction in both CNP (mRNA) and NPR-C (mRNA and protein) levels in CLI tissue (NPR-B mRNA expression was also reduced; Figure 1A and Figure IIIA in the online-only Data Supplement). Furthermore, NPR-C protein expression, which colocalized with the cell membrane (wheat germ agglutinin-positive) and vascular endothelium (CD31-positive) was markedly reduced around both the myofibers ( Figure 1B ) and blood vessels ( Figure 1C ) in gastrocnemius samples of patients with CLI in comparison with healthy controls.
CNP Promotes Angiogenesis in Human and Murine Endothelial Cells via NPR-C
Accordingly, exogenous CNP increased the rate of migration of HUVECs in a concentration-dependent manner with the highest concentration producing a response with a time course and magnitude similar to the archetypal proangiogenic mediator, VEGF (Figure 1D and 1E ). Pharmacological administration of CNP also promoted tubule formation in HUVEC with a maximal effect commensurate with that produced by VEGF ( Figure 1F ). Combination of CNP and VEGF result in a modest additive effect on tubule-forming activity across genotypes ( Figure IVA in the online-only Data Supplement), suggesting that the 2 mediators are not interdependent. To substantiate the thesis that NPR-C activation underpins the proangiogenic action of CNP, genetic and pharmacological deletion of NPR-C was used in HUVEC to demonstrate an antiangiogenic phenotype. Indeed, in the presence of both the selective NPR-C antagonist M372049 27 ( Figure 1G and 1H) and small interfering RNA knockdown of NPR-C ( Figure 1I and Figure ) also produced an essentially identical increase in tubule formation that was sensitive to blockade by M372049 ( Figure IVB in the online-only Data Supplement). These data establish the proangiogenic capacity of CNP-NPR-C signaling in human endothelial cells and provide direct evidence that such a pathway is downregulated in human PAD/CLI. It is interesting to note that increases in tubule formation driven by ANP were not sensitive to blockade by M372049 ( Figure V in the online-only Data Supplement), intimating that this member of the natriuretic peptide family is unable to trigger angiogenic behavior in endothelial cells via NPR-C; this finding fits well with previous work identifying NPR-A/cGMP/PKG signaling as the key pathway underpinning ANP/BNPdriven revascularization after ischemia. 22, 28 To reiterate the importance of endothelium-derived CNP in angiogenic signaling, murine PMECs were isolated from ecCNP -/-animals, in which CNP is conditionally deleted in endothelial cells, and from WT littermates, and used to investigate in vitro migration and tubule formation. Consistent with the HUVEC data, CNP promoted migration in a scratch closure assay in WT murine PMECs in a concentration-dependent manner and with a similar maximal activity to VEGF ( ure 2B). However, exogenous CNP was able to increase the rate of scratch closure in cells from both genotypes to a similar extent to that observed in HUVEC (Figure 2A and 2C). Of note, the relative increase in migration in PMECs from ecCNP -/-mice was greater than that in WT cells, suggesting a sensitization of the underlying signaling pathway. PMECs from mice with global deletion of NPR-B or NPR-C were used to confirm the NPR subtype underlying the actions of CNP on endothelial migration and tube formation. PMECs from NPR-B -/-mice had an ORIGINAL RESEARCH ARTICLE intrinsic migratory capacity equivalent to WT ( Figure 2D ), whereas PMECs from NPR-C -/-animals exhibited a significantly slower scratch closure ( Figure 2D ). Although pharmacological addition of CNP promoted endothelial migration in NPR-B -/-cells ( Figure 2E ), it had no significant effect in NPR-C -/-cells ( Figure 2F ). This receptor-specific activity was recapitulated in assays of endothelial tubule formation, in which ecCNP -/-and NPR-C -/-cells displayed significantly impaired intrinsic tubule-forming activity in comparison with cells from WT and NPR-B -/-mice (Figure 2G and 2H) . Likewise, the ability of exogenous CNP to stimulate tubule development was only apparent in WT, ecCNP -/-, and NPR-B -/-cells, but was abrogated in cells from NPR-C -/-mice ( Figure 2G and 2H ). These findings corroborate a fundamental role for endothelial CNP-NPR-C signaling in stimulating cellular functions essential for angiogenesis.
De Novo Sprouting Ex Vivo and Neovascularization In Vivo Is Diminished in Vessels Lacking Either Endothelial CNP or NPR-C
A more complex ex vivo model of angiogenic sprouting was subsequently used to verify this novel angiogenic role for endothelium-derived CNP. Aortic sprouting in vessel segments from WT animals was potentiated in a concentration-dependent manner by treatment with CNP with a time course and response magnitude equivalent to those of VEGF ( Figure 3A and 3B) . Furthermore, spontaneous sprouting was overtly impaired in aortic rings from ecCNP -/-and NPR-C -/-mice in comparison with WT animals ( Figure 3C ). In sharp contrast, in vessel segments from NPR-B -/-mice, de novo sprouting was similar to that in WT aortic rings ( Figure 3C ). The requirement of NPR-C activation for the proangiogenic action of CNP in this assay was demonstrated by the failure of exogenous CNP to promote aortic sprouting in NPR-C -/-aortic rings, in comparison with vessels from ecCNP -/-and NPR-B -/-mice ( Figure 3C ). These data dovetail well with the rudimentary in vitro models (above) establishing that CNP-NPR-C signaling is critical to the angiogenic potential of the endothelium.
Next, we investigated the influence of CNP on neovascularization in vivo using an assay in which subcutaneously implanted matrigel plugs exhibit a significant increase in de novo vessel formation and hemoglobin content (as an index of mature, perfused vasculature; Figure 3D through 3F). In accord with our data from aortic ring assays, CNP caused a striking stimulation of neovascularization in matrigel plugs implanted in WT, ecCNP -/-, and NPR-B -/-mice, but had no significant effect on angiogenesis in NPR-C -/-mice (Figure 3D through 3F and Figure VII in the online-only Data Supplement). These findings, taken together with our data from cell-based and aortic ring assays, provide strong evidence that CNP potently promotes angiogenesis specifically via the NPR-C subtype.
CNP Governs Angiogenesis via NPR-C-Dependent Activation of ERK1/2 and Akt/Protein Kinase B
We have previously reported that NPR-C-dependent ERK1/2 phosphorylation is key to augmenting CNPdriven endothelial cell proliferation. 16 In accord, we investigated if a similar transduction pathway is responsible for the angiogenic actions of CNP. The ability of exogenous CNP to trigger tubule formation in PMECs and aortas from WT animals was significantly attenuated by the selective ERK1/2 inhibitor, PD98059 (Figure 4A and 4B ). The functional blockade by PD98059 was paralleled by a reduced ERK1/2 phosphorylation in response to CNP ( Figure 4C ). Endothelium-derived CNP was also required for basal ERK1/2 activation because PMEC from ecCNP -/-mice exhibited a significantly lower basal ERK1/2 phosphorylation than WT controls (Figure 4D) , an effect that was fully rescued by addition of exogenous CNP, which stimulated ERK1/2 activation to a similar extent in WT and ecCNP -/-cells ( Figure 4D ). The role of NPR-C in conveying CNP angiogenic signaling was investigated using the selective NPR-C antagonist, M372049. Treatment with M372049 completely inhibited CNP-induced ERK1/2 activation in WT PMEC (Figure 4E) . The mechanism linking NPR-C activation with ERK1/2 phosphorylation was examined with the use of the G i blocker pertussis toxin. As shown in Figure 4F , pertussis toxin strongly inhibited the ability of CNP to trigger ERK1/2 phosphorylation. We next investigated the role of the PI3K/Akt (protein kinase B) pathway, which is essential to the migratory capacity of endothelial cells. 29 Here, the ability of CNP to promote endothelial tubule formation and aortic sprouting was blocked in the presence of the selective PI3K inhibitor wortmannin ( Figure 4G and 4H) . In addition, studies with the selective inhibitor AS605240 revealed that, specifically, PI3Kγ activation is a prerequisite for CNP-driven tubule formation and aortic sprouting ( Figure VIIIA and VIIIB in the online-only Data Supplement). Basal Akt/ protein kinase B phosphorylation was also significantly reduced in endothelial cells from ecCNP -/-and NPR-C -/-mice, but increased by incubation with CNP ( Figure 4I ). Finally, to rule out a role for NPR-B/cGMP signaling in the proangiogenic actions of CNP, tubule formation and aortic sprouting were investigated in the presence of the PKG inhibitor KT5823; in this setting, CNP-facilitated responses were unchanged ( Figure VIIIC and VIIID in the online-only Data Supplement). In concert, these observations establish that CNP-NPR-C-G i coupling activates ERK1/2 and PI3Kγ/Akt/protein kinase B signaling to promote angiogenesis, similar to the downstream pathways activated by VEGF and other well-established proangiogenic mediators. 3 These data are also consistent with previous reports linking NPR-C activation with G i signaling in the vasculature. 30 
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Restoration of Blood Flow After Hindlimb Ischemia Is Impaired by Loss of Endothelium-Derived CNP but Can Be Reversed by Targeting NPR-C Pharmacologically
We used a well-established in vivo model of CLI to verify that endothelium-derived CNP, via NPR-C activation, is a prerequisite for optimal engagement of restorative angiogenic and arteriogenic pathways after pathological ischemia in vivo. After unilateral ligation and excision of the femoral artery (HLI), mice undergo a pronounced remodeling to restore an adequate blood supply that supports essentially complete recovery (ie, perfusion, motor function) over 28 days. Consistent with the findings in human tissue, the expression of both CNP and VEGF-A mRNA was reduced, with a marked increase in hypoxia-inducible factor 1α, Bax, VCAM-1, interleukin-6, and C-C Motif Chemokine Ligand 2 in the ischemic gastrocnemius muscle at day 3 after HLI in comparison with the nonischemic tissue in WT mice, with a subsequent increase in expression at day 7 (Figure 5A and Figure IIB and IIC in the online-only Data Supplement). ecCNP -/-mice exhibited a significantly impaired recovery after HLI in terms of perfusion (Fig- ure 5B and 5C and Figure IXA in the online-only Data Supplement), blood vessel density (ie, capillary/myofiber ratio; Figure 5D and 5E), fibrosis (ie, collagen deposition; Figure 5F and 5G), and regeneration of muscle fibers ( Figure 5H and 5I ). This adverse phenotype in ecCNP -/-animals could be rescued by pharmacological administration of CNP ( Figure 5B through 5I) . Indeed, exogenous CNP improved indices of injury in WT mice implying that therapeutic targeting of the CNP-NPR-C pathway is likely to be of benefit above and beyond any endogenous signaling (paralleling observations in PMEC where CNP-stimulated migration in ecCNP -/-was greater than that in WT). NPR-C mRNA and protein expression followed a temporal profile identical to CNP and VEGF-A, with an initial reduction (day 3) followed by a significant increase (day 7; Figure 6A and Figures   IIB, IIC , & IIIB in the online-only Data Supplement), suggesting that the expression of CNP-NPR-C signaling is coordinated with the angiogenic response. However, NPR-C -/-mice presented with an overly more injurious phenotype after being subjected to HLI ( Figure 6B through 6I). It is significant that, in sharp contrast to ecCNP -/-animals, pharmacological administration of CNP did not rescue phenotype in NPR-C -/-mice (Figure 6B through 6I and Figure IXB in the online-only Data Supplement). These data substantiate a proangiogenic, proremodeling function for endothelium-derived CNP in vivo and verify that the activation of NPR-C underpins this process. Moreover, strategies aimed at pharmacologically activating NPR-C are likely to be of benefit in patients with CLI.
Reponses to Vessel Injury and Wound Healing In Vivo Are Impaired in ecCNP -/-and NPR-C -/-Mice
To demonstrate a more widespread role for endothelial CNP in the host defense response to injury, we used 2 further independent, etiologically distinct preclinical models. First, we examined the remodeling in wireinjured murine carotid arteries (akin to percutaneous coronary intervention). In this setting, WT mice exhibited a typical, marked intimal hyperplasia after injury that was significantly exacerbated in ecCNP -/-and NPR-C -/-animals ( Figure 7A through 7C) . Indeed, the intimal thickening was particularly pronounced in NPR-C -/-mice, with almost complete occlusion of the vessel after injury ( Figure 7C ). Second, we investigated cutaneous wound healing after a biopsy on the dorsal skin. Here, wound closure was essentially complete in WT animals after 7 days (Figure 7D through 7G) . However, this reparative process was markedly delayed in both ecCNP -/-( Figure 7D and 7E) and NPR-C -/-mice ( Figure 7F and 7G). These observations support the conclusion that CNP-NPR-C signaling has an important role in the tissue repair responses to injury, and warrants further attention from both a (patho)physiological and therapeutic perspective.
DISCUSSION
Ischemic cardiovascular disease, typified by PAD and CLI, myocardial infarction, and stroke, represents a major cause of global morbidity and mortality. 31 Restoration of adequate blood supply to hypoxic tissue, via complementary angiogenic and arteriogenic mechanisms, in response to ischemia is decisive for both host repair and therapeutic intervention. Previous attempts to harness these endogenous corrective pathways to improve outcome in PAD have focused primarily on promoting the actions of VEGF, yet these strategies have proven large-ORIGINAL RESEARCH ARTICLE Figure 5 . Restoration of blood flow after hindlimb ischemia is impaired in endothelium-specific C-type natriuretic peptide (CNP) knockout mice but can be reversed by pharmacological administration of CNP. A, The mRNA expression of CNP is reduced in ischemic gastrocnemius muscles (HLI) from wild-type (WT) mice, in comparison with nonischemic controls (control), with a significant increase at day 7 after HLI (n=5-7). B and C, Restoration of leg blood flow is impaired in endothelium-specific CNP knockout (ecCNP ly ineffective clinically, whether based on cells, genes, or small molecules. [6] [7] [8] Herein, we establish a previously undefined role for endothelium-derived CNP in angiogenesis and vascular remodeling. This critical function is dependent on the activation of NPR-C and, via G i coupling, the stimulation of the classical ERK1/2 and Akt/ protein kinase B pathways that are harnessed by many factors promoting endothelial proliferation, migration, and survival, including VEGF. 3, 32 Clinical evidence using gastrocnemius muscle biopsies from patients with CLI confirmed that expression of CNP and NPR-C is downregulated, matching that observed at the earliest time points after HLI in the experimental model; yet mice are able to upregulate CNP and NPR-C expression to coincide with the angiogenic and arteriogenic response to ischemia. Diminution of CNP/NPR-C signaling in CLI may therefore underpin the inability to promote compensatory angiogenesis and vascular remodeling to maintain appropriate blood supply. However, targeting this pathway pharmacologically facilitates angiogenesis and vascular remodeling, implying that therapeutic approaches triggering NPR-C activation are likely to be of benefit in PAD/CLI and other ischemic disorders including myocardial infarction.
Endothelium-derived CNP plays a fundamental role in regulating vascular function, local blood flow, systemic blood pressure, and the reactivity of circulating leukocytes and platelets. [10] [11] [12] Previous work has also suggested that this peptide contributes to the maintenance of blood vessel integrity and response to injury. [17] [18] [19] [20] [21] [22] The signaling pathway(s) underpinning these vasoprotective functions of CNP remain unresolved. In terms of endothelial and vascular smooth muscle cell hyperplasia, both cognate receptors, NPR-B and NPR-C, have been implicated. 33 However, in the present study, cells and tissues isolated from NPR-B -/-mice behaved in an identical fashion to WT in complementary in vitro and in vivo models of angiogenesis, whether in terms of intrinsic activity or in response to exogenous CNP; the proangiogenic effects of CNP in vitro were also insensitive to PKG inhibition. These findings demonstrate that NPR-B-triggered cGMP formation is unlikely to underlie the restorative capacity of CNP. Rather, genetic deletion of NPR-C produced an identical antiangiogenic, antiarteriogenic phenotype, both in vitro and in vivo, akin to that observed in mice lacking endothelium-derived CNP. This NPR-C dependency adds to the growing number of physiological signaling roles of this G protein-coupled receptor traditionally thought solely to clear natriuretic peptides from the circulation. 34 Evidence now supports the conclusion that NPR-C is a cellular transduction trigger in the cardiovascular system, regulating diverse processes including cell growth, 16 oxidative stress, 35 and sinoatrial node conduction. 36 Moreover, G i coupling appears to mediate the majority of these actions. 30 Herein, we show that the proangiogenic effects of CNP, driven through NPR-C activation, are also G i dependent and involve signaling via both ERK1/2 and PI3Kγ/Akt/protein kinase B, pathways well established to synchronize angiogenesis and arteriogenesis 3, 37 ( Figure X in the onlineonly Data Supplement). These observations fit well with the profile of CNP and NPR-C expression in response to HLI (herein and 38 ), first falling and then increasing in a temporal manner that aligns with the restoration of blood flow and influence of VEGF, and thereby provide new mechanistic insight into the vasoprotective role of this receptor. It is intriguing that the loss of this protective phenotype observed in vitro, and to some extent in vivo, appeared to be more severe in global NPR-C -/-cells and tissues than in those from ecCNP -/-mice. This differential activity may stem, in part, from an incomplete deletion of CNP from endothelial cells in the transgenic strain used (≈80% 10 ) but may also originate from the loss of constitutive receptor activity, a characteristic of G protein-coupled receptors, in NPR-C -/-animals. Whether NPR-A/cGMP/PKG signaling in response to ANP or BNP, which is established to promote revascularization after ischemia, 22, 28 might offset the loss of CNP/ NPR-C signaling remains to be determined. However, the antiangiogenic consequence of NPR-C deletion implies that increased activity of ANP/BNP (acting via NPR-A/cGMP/PKG) resulting from elimination of the clearance capacity of NPR-C is not sufficient to compensate overtly. Cursory investigation herein suggests that ANP is also unable to exert a similar proangiogenic effect via NPR-C.
In addition, we demonstrate clear therapeutic potential for pharmacologically activating NPR-C in PAD and other ischemic cardiovascular disorders. Administration of CNP (ie, an NPR-C agonist) is able to significantly improve revascularization in vivo after ischemia, and the multifaceted nature of this protective influence was highlighted by improvement in several indices of disease severity, including improved leg and paw perfusion, increased vessel density, reduced fibrosis, and accelerated myofiber regeneration. In the setting of PAD/CLI, the antileukocyte and antiplatelet actions of endothelial-derived CNP (via NPR-C) 10 will proffer an additional level of protection from prospective atherosclerotic occlusion and represent additional therapeutic value. One possible caveat is the diminished NPR-C expression observed in amputated limbs from patients with CLI, which might limit the efficacy of CNP/NPR-C-based treatments. However, at initial stages of PAD (eg, onset of claudication), the components of the signaling pathway are likely to be expressed at a higher level, advocating early intervention. Moreover, the human CLI tissue was derived from extensively necrotic areas and it is conceivable that, in the border region between healthy and diseased limb, NPR-C expression is higher and therefore more tractable in terms of therapy (comparable to day 7 after HLI). Indeed, herein CNP
ORIGINAL RESEARCH ARTICLE
delivery in the murine model was initiated at the nadir of NPR-C expression which matches that in CLI tissue. Regardless, pharmacological administration of CNP is incredibly effective at restoring blood flow, providing proof-of-concept that this strategy might be effective in patients with CLI. It is interesting to note that there appears to be a reciprocal relationship between CNP and VEGF in the regulation of angiogenesis. VEGF inhibits CNP secretion from endothelial cells, 39 whereas CNP (and other natriuretic peptides) have been reported to inhibit VEGF production. 40 Whether this represents temporal or spatial feedback communication between the parallel pathways remains to be explored, but a linking mechanism may involve transforming growth factor β 1 signaling, which is key to tissue repair after ischemia, because both CNP and VEGF have transforming growth factor β 1 -responsive promoters. 41 A further common mechanism of regulation is likely provided by hypoxia-inducible factor 1α, which is known to be a key inducer of VEGF transcription (in addition to its downstream signaling components), 42 and which also upregulates natriuretic peptide expression. 15 Indeed, the Nppc (CNP) promoter region contains several hypoxia response elements. Regardless, CNP-NPR-C signaling appears to represent a novel, innate angiogenic pathway independent of and equal to the magnitude of that proffered by VEGF (at least in assays described herein).
The G i -linked reparative action of CNP-NPR-C closely resembles the proangiogenic processes regulated by growth factors such as sphingosine 1-phosphate and insulin-like growth factor, 43, 44 both of which signal via single-transmembrane domain G i -coupled receptors. Thus, the present study suggests that NPR-C, which similarly belongs to this atypical type 1 membrane G protein-coupled receptor family, can also be considered to function as a growth factor receptor in the context of angiogenesis (in contrast to more acute, functional changes in vascular tone and blood pressure 10 ). Furthermore, we provide compelling evidence that CNP-NPR-C signaling is a widespread mechanism invoked to expedite tissue repair after injury. In 2 etiologically distinct experimental models, wire-induced carotid damage and wound healing, recovery from insult was overtly impaired in animals endothelial CNP or global NPR-C null mutants. These more complex systems illustrate the significant contribution of CNP-NPR-C signaling to tissue repair and implicate additional roles above and beyond the processes of angiogenesis and arteriogenesis (the central focus of this study). Indeed, a previous report showed that pharmacological addition of CNP promotes angiogenesis in the skin of mice (albeit accompanied by slowed wound healing) 45 and that CNP expression is upregulated in human coronary atherosclerotic lesions 46 and in the neointima after percutaneous coronary intervention. 47 These latter vasoprotective facets of CNP biology that drive vessel repair highlight the opposing effects of CNP on endothelial (stimulatory) and vascular smooth muscle/myofibroblast (inhibitory) proliferation. In turn, this may result from altered expression patterns of NPR-B and NPR-C on these cells; NPR-B is highly expressed in all cell types, whereas NPR-C expression is higher on endothelial cells than on vascular smooth muscle. 48 This dual activity may also underpin the more severe phenotype of global NPR-C -/-, versus ecCNP -/-mice in these particular injurious experimental models.
In sum, endothelium-derived CNP plays a pivotal role in angiogenesis and vascular remodeling after ischemia via specific activation of NPR-C, G i stimulation, and triggering of ERK1/2 and PI3Kγ/Akt/protein kinase B phosphorylation ( Figure X in the online-only Data Supplement). Furthermore, pharmacological targeting of NPR-C promotes vascular repair after injury and offers a novel avenue for the therapy of PAD and other ischemic cardiovascular disorders.
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